Thu, Apr 24, 2014, 5:23 AM EDT - U.S. Markets open in 4 hrs 7 mins


% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

  • troyanderson747 troyanderson747 Aug 30, 2012 12:17 PM Flag

    ICT-107 sales potential: Over $500 million

    Analysts project annual sales for ICT-107 to be around $500 million (read Zack's June 2012 IMUC research report which includes a $7 price target). However, ICT-107's pricing power and addressable market suggests sales potential that far exceeds $500 million. Look at other GBM drugs for comparison. Temodar, which is the only drug approved to treat newly diagnosed GBM, generates over $1 billion in sales annually. The chemotherapy agent only improves median overall survival by 2.5 months, whereas ICT-107 has been shown to improve survival by about 2 years (albeit in a single-center, uncontrolled, Phase 1 study). Avastin, which is approved for patients with recurrent GBM, earned over a mind-boggling $7 billion. However, Avastin is indicated for multiple cancers (e.g., colorectal, lung and renal), which aids in the large revenue. ICT-107 targets antigens that are expressed on several cancers other than GBM, such as melanoma and breast. So if the use for ICT-107 is expanded to other cancer indications then IMUC should return much larger sales than $500 million per year.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.23-0.02(-1.60%)Apr 23 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.